Current Diabetes Reports

, 8:486 | Cite as

Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians

  • Meda E. Pavkov
  • William C. Knowler
  • Robert L. Hanson
  • Robert G. Nelson


Diabetes affects American Indians disproportionately compared with other racial/ethnic groups in the United States and is almost exclusively type 2 diabetes. Much of our knowledge about diabetes in American Indians comes from studies in a few tribes. The most extensively studied American Indians are the Pima Indians from the Gila River Indian Community in Arizona, who participated in a longitudinal study of diabetes and its complications between 1965 and 2007. They have one of the highest reported incidence and prevalence of type 2 diabetes in the world, and kidney disease attributable to diabetes is a major cause of morbidity and mortality. In this article, we examine the course, determinants, and trends of diabetic kidney disease in American Indians, with special emphasis on studies conducted in the Pima Indians. We also review therapeutic strategies for managing diabetic kidney disease.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.Google Scholar
  2. 2.
    Xu J, Knowler WC, Devereux RB, et al.: Albuminuria within the “normal” range and risk of cardiovascular disease and death in American Indians: the Strong Heart Study. Am J Kidney Dis 2007, 49:208–216.PubMedCrossRefGoogle Scholar
  3. 3.
    Bella JN, Roman MJ, Fabsitz R, et al.: Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes. The Strong Heart Study. J Am Coll Cardiol 2003, 41:2022–2028.PubMedCrossRefGoogle Scholar
  4. 4.
    Robbins DC, Knowler WC, Lee ET, et al.: Regional differences in albuminuria among American Indians: an epidemic of renal disease Kidney Int 1996, 49:557–563.PubMedCrossRefGoogle Scholar
  5. 5.
    Hirata-Dulas CA, Rith-Najarian SJ, McIntyre MC, et al.: Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. Clin Nephrol 1996, 46:92–98.PubMedGoogle Scholar
  6. 6.
    Sosenko JM, Dongsheng H, Welty T, et al.: Albuminuria in recent-onset type 2 diabetes. The Strong Heart Study. Diabetes Care 2002, 51:1078–1084.CrossRefGoogle Scholar
  7. 7.
    Scavini M, Shah VO, Stidley CA, et al.: Kidney disease among the Zuni Indians: the Zuni Kidney Project. Kidney Int Suppl 2005, 68:S126–S131.CrossRefGoogle Scholar
  8. 8.
    Nelson RG, Kunzelman CL, Pettitt DJ, et al.: Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 1989, 32:870–876.PubMedCrossRefGoogle Scholar
  9. 9.
    Hoehner CM, Greenlund KJ, Rith-Najarian S, et al.: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002, 13:1626–1634.PubMedCrossRefGoogle Scholar
  10. 10.
    U.S. Renal Data System: USRDS 2007 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.Google Scholar
  11. 11.
    Pavkov ME, Bennett PH, Sievers ML, et al.: Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes. Kidney Int 2005, 68:1267–1274.PubMedCrossRefGoogle Scholar
  12. 12.
    Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of Veterans. Diabetes Care 2003, 26:2392–2399.PubMedCrossRefGoogle Scholar
  13. 13.
    Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996, 335:1636–1642.PubMedCrossRefGoogle Scholar
  14. 14.
    Lemley KV: A basis for accelerated progression of diabetic nephropathy in Pima Indians. Kidney Int 2003, 63(Suppl 83):S38–S42.CrossRefGoogle Scholar
  15. 15.
    Eddy AA: Proteinuria and interstitial injury. Nephrol Dial Transplant 2004, 19:277–281.PubMedCrossRefGoogle Scholar
  16. 16.
    Becker JU, Hoerning A, Schmid KW, Hoyer PF: Immigrating progenitor cells contribute to human podocyte turnover. Kidney Int 2007, 72:1468–1473.PubMedCrossRefGoogle Scholar
  17. 17.
    Pagtalunan ME, Miller PL, Jumping-Eagle S, et al.: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342–348.PubMedCrossRefGoogle Scholar
  18. 18.
    Lemley KV, Abdullah I, Myers BD, et al.: Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000, 58:1228–1237.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanson RL, Elston RC, Pettitt DJ, et al.: Segregation analysis of non-insulin-dependent diabetes mellitus in Pima Indians: evidence for a major-gene effect. Am J Hum Genet 1995, 57:160–170.PubMedGoogle Scholar
  20. 20.
    McCance DR, Hanson RL, Pettitt DJ, et al.: Diabetic nephropathy: a risk factor for diabetes mellitus in offspring. Diabetologia 1995, 38:221–226.PubMedCrossRefGoogle Scholar
  21. 21.
    Hanson RL, Craig DW, Millis MP, et al.: Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 2007, 56:975–983.PubMedCrossRefGoogle Scholar
  22. 22.
    Conrad DF, Jakobsson M, Coop G, et al.: A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 2006, 38:1251–1260.PubMedCrossRefGoogle Scholar
  23. 23.
    Iyengar SK, Abboud HE, Goddard KAB, et al.: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 2007, 56:1577–1585.PubMedCrossRefGoogle Scholar
  24. 24.
    Schelling JR, Abboud HE, Nicholas SB, et al.: Genome-wide scan for estimated GFR in multi-ethnic diabetic populations: The Family Investigation of Nephropathy and Diabetes. Diabetes 2008, 57:235–243.PubMedCrossRefGoogle Scholar
  25. 25.
    Nelson RG: Intrauterine determinants of diabetic kidney disease in disadvantaged populations. Kidney Int 2003, 83:S13–S16.CrossRefGoogle Scholar
  26. 26.
    Tran S, Chen YW, Chenier I, et al.: Maternal diabetes modulates renal morphogenesis in offspring. J Am Soc Nephrol 2008, 19:943–952.PubMedCrossRefGoogle Scholar
  27. 27.
    Abrahamson DR, Steenhard BM: Perinatal nephron programming is not so sweet in maternal diabetes. J Am Soc Nephrol 2008, 19:837–839.PubMedCrossRefGoogle Scholar
  28. 28.
    Luyckx VA, Brenner BM: Low birth weight, nephron number, and kidney disease. Kidney Int 2005, 68:S68–S77.CrossRefGoogle Scholar
  29. 29.
    Nelson RG, Knowler WC, Pettitt DJ, et al.: Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995, 18:182–187.PubMedCrossRefGoogle Scholar
  30. 30.
    Nelson RG, Pettitt DJ, de Courten MP, et al.: Parental hypertension and proteinuria in Pima Indians with NIDDM. Diabetologia 1996, 39:433–438.PubMedCrossRefGoogle Scholar
  31. 31.
    Nelson RG, Pettitt DJ, Baird HR, et al.: Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993, 36:998–1001.PubMedCrossRefGoogle Scholar
  32. 32.
    Knowler WC, Pettitt DJ, Saad MF, Bennett PH: Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev 1990, 6:1–27.PubMedCrossRefGoogle Scholar
  33. 33.
    Pavkov ME, Hanson RL, Knowler WC, et al.: Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 2007, 30:1758–1763.PubMedCrossRefGoogle Scholar
  34. 34.
    Pavkov ME, Bennett PH, Knowler WC, et al.: Effect of youthonset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006, 296:421–426.PubMedCrossRefGoogle Scholar
  35. 35.
    Krakoff J, Lindsay RS, Looker HC, et al.: Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003, 26:76–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Shultis WA, Weil EJ, Looker HC, et al.: Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care 2007, 30:306–311.PubMedCrossRefGoogle Scholar
  37. 37.
    Burrows NR, Li Y, Williams DE: Racial and ethnic differences in trends of end-stage renal disease: United States, 1995 to 2005. Adv Chronic Kidney Dis 2008, 15:147–152.PubMedCrossRefGoogle Scholar
  38. 38.
    Narva AS: Reducing the burden of chronic kidney disease among American Indians. Adv Chronic Kidney Dis 2008, 15:168–173.PubMedCrossRefGoogle Scholar
  39. 39.
    Pavkov ME, Knowler WC, Bennett PH, et al.: Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006, 70:1840–1846.PubMedCrossRefGoogle Scholar
  40. 40.
    Pavkov ME, Knowler WC, Hanson RL, et al.: Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis 2008, 51:759–766.PubMedCrossRefGoogle Scholar
  41. 41.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
  42. 42.
    Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA: Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007, 72:1367–1373.PubMedCrossRefGoogle Scholar
  43. 43.
    Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560–2572.Google Scholar
  44. 44.
    Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002, 106:672–678.PubMedCrossRefGoogle Scholar
  45. 45.
    Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 2002, 61:1086–1097.PubMedCrossRefGoogle Scholar
  46. 46.
    Mauer M, Zinman B, Gardiner R, et al.: The renin-angiotensin system study (RASS): effects of enalapril and losartan on diabetic nephropathy and diabetic retinopathy in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Presented at the American Diabetes Association 68th Scientific Sessions. San Francisco, CA; June 6–10, 2008.Google Scholar
  47. 47.
    Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.PubMedCrossRefGoogle Scholar
  48. 48.
    Brenner BM, Cooper ME, DeZeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.PubMedCrossRefGoogle Scholar
  49. 49.
    Mogensen CE, Neldam S, Takkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.PubMedCrossRefGoogle Scholar
  50. 50.
    Telmisartan, Ramipril, or both in patients at high risk for vascular events. The ONTARGET Investigators [no authors listed]. N Engl J Med 2008, 358:1547–1559.Google Scholar
  51. 51.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.PubMedCrossRefGoogle Scholar
  52. 52.
    Gæde P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Meda E. Pavkov
  • William C. Knowler
  • Robert L. Hanson
  • Robert G. Nelson
    • 1
  1. 1.Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthPhoenixUSA

Personalised recommendations